Table 1.

Baseline characteristics of DLBCL patients in a PET+ PR before autologous transplantation

No ECFECFP
No. of patients 67 182  
No. of centers 39 64  
Patient age    
 Μedian (range), y 63 (39-77) 57 (20-76) <.001 
 ≥65 y, n (%) 29 (43.3) 47 (25.8)  
Males 38 (56.7) 106 (58.2) .83 
Patient race   .20 
 White 56 (83.6) 134 (73.6)  
 African American 7 (10.4) 34 (18.7)  
 Other* 4 (6) 9 (4.9)  
 Missing data 5 (2.8)  
Karnofsky performance score    
 ≥90 32 (47.8) 94 (51.6) .83 
 Missing data 2 (3) 4 (2.2)  
Disease at diagnosis    
 Stage III-IV 36 (53.7) 135 (74.2) .003 
 Missing data 5 (7.5) 14 (7.7)  
LDH    
 Elevated at diagnosis 9 (13.4) 24 (13.2) .14 
 Missing data 45 (67.2) 100 (54.9)  
Lines of therapy prior to HCT, median (range), n 2 (1-5) 2 (1-5) .65 
Bone marrow involvement at diagnosis    
 No 52 (77.6) 143 (78.6) .53 
 Missing data 7 (10.4) 12 (6.6)  
Extranodal involvement at diagnosis    
 Yes 31 (46.3) 105 (57.7) .24 
 Missing data 7 (10.4) 12 (6.6)  
Time from diagnosis to HCT, median (range), mo 35 (16-149) 11 (3-146) <.001 
Residual nodal bulk at HCT   .18 
 Nonbulky (<5 cm) 24 (35.8) 87 (47.8)  
 Bulky (≥5 cm) 7 (10.5) 22 (12.1)  
 Not reported 36 (53.7) 73 (40.1)  
Conditioning regimen   .88 
 BEAM 55 (82.1) 147 (80.8)  
 Bu/Cy 7 (10.4) 23 (12.6)  
 CBV 5 (7.5) 12 (6.6)  
Primary refractory after first line of therapy 144 (79.1) <.001 
Follow-up of survivors, median (range), mo 69 (5-123) 53 (10-149)  
No ECFECFP
No. of patients 67 182  
No. of centers 39 64  
Patient age    
 Μedian (range), y 63 (39-77) 57 (20-76) <.001 
 ≥65 y, n (%) 29 (43.3) 47 (25.8)  
Males 38 (56.7) 106 (58.2) .83 
Patient race   .20 
 White 56 (83.6) 134 (73.6)  
 African American 7 (10.4) 34 (18.7)  
 Other* 4 (6) 9 (4.9)  
 Missing data 5 (2.8)  
Karnofsky performance score    
 ≥90 32 (47.8) 94 (51.6) .83 
 Missing data 2 (3) 4 (2.2)  
Disease at diagnosis    
 Stage III-IV 36 (53.7) 135 (74.2) .003 
 Missing data 5 (7.5) 14 (7.7)  
LDH    
 Elevated at diagnosis 9 (13.4) 24 (13.2) .14 
 Missing data 45 (67.2) 100 (54.9)  
Lines of therapy prior to HCT, median (range), n 2 (1-5) 2 (1-5) .65 
Bone marrow involvement at diagnosis    
 No 52 (77.6) 143 (78.6) .53 
 Missing data 7 (10.4) 12 (6.6)  
Extranodal involvement at diagnosis    
 Yes 31 (46.3) 105 (57.7) .24 
 Missing data 7 (10.4) 12 (6.6)  
Time from diagnosis to HCT, median (range), mo 35 (16-149) 11 (3-146) <.001 
Residual nodal bulk at HCT   .18 
 Nonbulky (<5 cm) 24 (35.8) 87 (47.8)  
 Bulky (≥5 cm) 7 (10.5) 22 (12.1)  
 Not reported 36 (53.7) 73 (40.1)  
Conditioning regimen   .88 
 BEAM 55 (82.1) 147 (80.8)  
 Bu/Cy 7 (10.4) 23 (12.6)  
 CBV 5 (7.5) 12 (6.6)  
Primary refractory after first line of therapy 144 (79.1) <.001 
Follow-up of survivors, median (range), mo 69 (5-123) 53 (10-149)  

Unless otherwise noted, data are n (%).

BEAM, carmustine, etoposide, cytarabine and melphalan; Bu/Cy, busulfan/cyclophosphamide; CBV, cyclophosphamide, carmustine, and etoposide; LDH: lactate dehydrogenase.

*

No ECF: 3 Asian and 1 Native American. ECF: 7 Asian, 1 Pacific Islander, and 1 Native American.

or Create an Account

Close Modal
Close Modal